The U.S. Food and Drug Administration approved a cold sore medication for the treatment of a cold, according to a study published in The American Journal of Public Health.

The drug, known as BX-1816, has been used for the past decade for treating chronic colds, such as a common cold, but it is not yet approved for use in the treatment or prevention of other colds.

The new study, conducted by scientists at Harvard University and the University of California, San Francisco, was led by Dr. Eric L. Hirsch, an associate professor of preventive medicine at Harvard Medical School and a member of the National Institute on Aging.

In the study, published in the journal Lancet, the scientists found that the drug was effective at preventing and treating the common cold.

The drug reduces inflammation in the upper airways, reduces the amount of time it takes to clear the airways and reduces the severity of symptoms, including coughs, sneezes and chest pain.

The researchers found that BX1816 was more effective than placebo in reducing the number of days in the cold months of the year when people experienced severe symptoms, such coughs and sneezing.

“Our study found that people who take BX, which is an anti-inflammatory medication, experience significant reductions in symptoms and can reduce the duration of the cold,” said Dr. Hoch, who was not involved in the study.”BX-16 has been in use for decades as a therapeutic tool for colds and other respiratory diseases.

In fact, we used the drug in our recent research in collaboration with other researchers at the National Institutes of Health.

The efficacy of BX in treating chronic coughs is encouraging, but the mechanism behind this effect is not well understood.

We are working to understand this mechanism, and we are also investigating other anti-inflammatories, including ibuprofen and acetaminophen, which have similar mechanisms of action.”

While BX16 is not a new treatment, it was not previously studied in the context of the common Cold, according Dr. John B. Ripps, a professor of medicine at the Harvard Medical College and director of the Division of Health Care Medicine at the Center for the Study of Infectious Diseases, and the senior author of the study published on April 13 in the Journal of the American Medical Association.

“This is an important new finding for the general public and is one that we hope will be a catalyst for more studies to help explain why the effectiveness of B-X16 in the prevention of coughs can be enhanced,” Ripp.

Hirsch and his colleagues began the research after they found that, in people with chronic cough and other cold-related conditions, BX was effective in preventing and reducing cough symptoms, as well as relieving coughs in those who had chronic cough.

The results of the current study support previous research that showed that B-x16 also was effective for preventing the common viral respiratory syndrome (VRS), the cold-like symptoms of viral respiratory infections that can include sneezles, coughs or sore throat.

They also found that treatment with BX effectively reduced the severity and frequency of the cough.

“There is evidence that Bx is effective in the acute and chronic cold-sores,” Dr. L. James Gilliland, professor of infectious diseases and senior author on the study and a researcher at the Mayo Clinic, said in a statement.

“This is a good example of the effectiveness, and potentially the benefits, of a common anti-VRS therapy, B-axyl-16-17, that we know has been effective for a long time.

The benefits of this treatment are that it is inexpensive and relatively easy to administer and has been found to be effective in many clinical trials.”

The researchers said BX could be a promising addition to the list of medicines being studied in a clinical trial, as research into the efficacy of anti-viral treatments is needed.

“We are interested in studying the efficacy and safety of the BX drug and other therapies that target the inflammatory pathways in the respiratory system,” Dr Gilliland said.

“As a general matter, there are many medicines that have been studied in people for the prevention or treatment of other infections, including COVID-19, the common virus that causes the common and deadly cold, and other viral respiratory disorders, but there are few in the human body that have shown a therapeutic benefit to prevent colds,” Raffaella DiClemente, chief executive of the British Lung Foundation, said.

DiClementes is a leading expert in the development and use of anti -viral medicines and said the current research was a promising development in this field.

“What is particularly exciting about this research is that it shows that BFX may be able to treat the common symptoms of colds in people who have the common respiratory disease,” she said.

The study involved more than 7,000 people, who